White Paper
Featured Topics
Lead story
Other featured articles
-
Federal Regulations of Cannabis for Public Health in the United States
State-level cannabis regulations have weak public health parameters compared to other countries, leaving consumers vulnerable.
Posted in -
Eliminating Small Marketplace Premiums Could Meaningfully Increase Insurance Coverage
Matthew Fiedler estimate that 404,000 Marketplace enrollees in the states served by HealthCare.gov currently owe a small positive premium (defined as a positive premium of less than 0.5% of the gross premium of the enrollee’s plan, which translates to around $3 per month on average).
Posted in -
The FDA Could Do More to Promote Generic Competition: Here’s How
USC-Brookings Schaeffer Initiative experts focus on three areas of FDA authority that could be refined to better promote generic competition: the Citizen Petition mechanism; the approval of so-called complex generic drugs; and the phenomenon known as “parking” under the Hatch-Waxman Act.
Posted in -
U.S. Consumers Overpay for Generic Drugs
Tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, are costing patients, employers and the government billions for what should be inexpensive medicines.
Posted in
ADDITIONAL WHITE PAPERS
-
The Economic Case for Federal Investment in COVID-19 Vaccines and Therapeutics Remains Strong
Schaeffer Initiative experts argue that there is a strong economic case for continued federal investment in COVID-19 vaccines and therapeutics.
-
Private Equity-Owned Air Ambulance Carriers Get Paid More Money and Are Out-of-Network More Often
In this analysis, we build on that prior work to document differences in allowed amounts, out-of-network prevalence, and the magnitude of potential surprise balance bills across ownership types in the helicopter air ambulance market.
-
Targeting Affordability in Healthcare: A Review of the Evidence
Health plans have many tools to reduce spending and therefore reduce plan premiums, which can improve the affordability of health insurance.
-
The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments
The 340B Drug Pricing Program allows eligible healthcare clinics and hospitals (“covered entities”) to purchase outpatient drugs at a 20-50% discount.
-
From Vision to Design in Advancing Medicare Payment Reform: A Blueprint for Population-Based Payments
With Medicare spending growth over the next decade expected to exceed GDP growth, the trust fund projected to be depleted in 2026, and evidence of persistent and pervasive waste and disparities in health care, attention has returned to the role of payment reform in controlling Medicare spending growth and driving more efficient and equitable care delivery.
-
Private Equity Investment as a Divining Rod for Market Failure: Policy Responses to Harmful Physician Practice Acquisitions
It is unclear whether private equity investment is itself a problem or whether, in the absence of private equity, other sources of capital—such as public equity, venture capital, health systems, and insurers—would similarly exploit existing market failures and legal loopholes in the healthcare system.